Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors

Gabriel Bricard, Valerie Cesson, Estelle Devevre, Hanifa Bouzourene, Catherine Barbey, Nathalie Rufer, Jin S. Im, Pedro M. Alves, Olivier Martinet, Nermin Halkic, Jean Charles Cerottini, Pedro Romero, Steven A. Porcelli, H. Robson MacDonald, Daniel E. Speiser

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Invariant NKT cells (iNKT cells) recognize glycolipid Ags via an invariant TCR α-chain and play a central role in various immune responses. Although human CD4+ and CD4- iNKT cell subsets both produce Th1 cytokines, the CD4+ subset displays an enhanced ability to secrete Th2 cytokines and shows regulatory activity. We performed an ex vivo analysis of blood, liver, and tumor iNKT cells from patients with hepatocellular carcinoma and metastases from uveal melanoma or colon carcinoma. Frequencies of Vα24/Vβ11 iNKT cells were increased in tumors, especially in patients with hepatocellular carcinoma. The proportions of CD4+, double negative, and CD8α+ iNKT cell subsets in the blood of patients were similar to those of healthy donors. However, we consistently found that the proportion of CD4+ iNKT cells increased gradually from blood to liver to tumor. Furthermore, CD4+ iNKT cell clones generated from healthy donors were functionally distinct from their CD4- counterparts, exhibiting higher Th2 cytokine production and lower cytolytic activity. Thus, in the tumor microenvironment the iNKT cell repertoire is modified by the enrichment of CD4+ iNKT cells, a subset able to generate Th2 cytokines that can inhibit the expansion of tumor Ag-specific CD8+ T cells. Because CD4+ iNKT cells appear inefficient in tumor defense and may even favor tumor growth and recurrence, novel iNKT-targeted therapies should restore CD4- iNKT cells at the tumor site and specifically induce Th1 cytokine production from all iNKT cell subsets.

Original languageEnglish (US)
Pages (from-to)5140-5151
Number of pages12
JournalJournal of Immunology
Volume182
Issue number8
DOIs
StatePublished - Apr 15 2009

Fingerprint

Natural Killer T-Cells
Neoplasms
Cytokines
Hepatocellular Carcinoma
Tissue Donors
Tumor Microenvironment
Liver
Glycolipids
Colon
Clone Cells

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Bricard, G., Cesson, V., Devevre, E., Bouzourene, H., Barbey, C., Rufer, N., ... Speiser, D. E. (2009). Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. Journal of Immunology, 182(8), 5140-5151. https://doi.org/10.4049/jimmunol.0711086

Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. / Bricard, Gabriel; Cesson, Valerie; Devevre, Estelle; Bouzourene, Hanifa; Barbey, Catherine; Rufer, Nathalie; Im, Jin S.; Alves, Pedro M.; Martinet, Olivier; Halkic, Nermin; Cerottini, Jean Charles; Romero, Pedro; Porcelli, Steven A.; MacDonald, H. Robson; Speiser, Daniel E.

In: Journal of Immunology, Vol. 182, No. 8, 15.04.2009, p. 5140-5151.

Research output: Contribution to journalArticle

Bricard, G, Cesson, V, Devevre, E, Bouzourene, H, Barbey, C, Rufer, N, Im, JS, Alves, PM, Martinet, O, Halkic, N, Cerottini, JC, Romero, P, Porcelli, SA, MacDonald, HR & Speiser, DE 2009, 'Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors', Journal of Immunology, vol. 182, no. 8, pp. 5140-5151. https://doi.org/10.4049/jimmunol.0711086
Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N et al. Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. Journal of Immunology. 2009 Apr 15;182(8):5140-5151. https://doi.org/10.4049/jimmunol.0711086
Bricard, Gabriel ; Cesson, Valerie ; Devevre, Estelle ; Bouzourene, Hanifa ; Barbey, Catherine ; Rufer, Nathalie ; Im, Jin S. ; Alves, Pedro M. ; Martinet, Olivier ; Halkic, Nermin ; Cerottini, Jean Charles ; Romero, Pedro ; Porcelli, Steven A. ; MacDonald, H. Robson ; Speiser, Daniel E. / Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. In: Journal of Immunology. 2009 ; Vol. 182, No. 8. pp. 5140-5151.
@article{b5b9fe0a37594111b46ba82d36e7b853,
title = "Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors",
abstract = "Invariant NKT cells (iNKT cells) recognize glycolipid Ags via an invariant TCR α-chain and play a central role in various immune responses. Although human CD4+ and CD4- iNKT cell subsets both produce Th1 cytokines, the CD4+ subset displays an enhanced ability to secrete Th2 cytokines and shows regulatory activity. We performed an ex vivo analysis of blood, liver, and tumor iNKT cells from patients with hepatocellular carcinoma and metastases from uveal melanoma or colon carcinoma. Frequencies of Vα24/Vβ11 iNKT cells were increased in tumors, especially in patients with hepatocellular carcinoma. The proportions of CD4+, double negative, and CD8α+ iNKT cell subsets in the blood of patients were similar to those of healthy donors. However, we consistently found that the proportion of CD4+ iNKT cells increased gradually from blood to liver to tumor. Furthermore, CD4+ iNKT cell clones generated from healthy donors were functionally distinct from their CD4- counterparts, exhibiting higher Th2 cytokine production and lower cytolytic activity. Thus, in the tumor microenvironment the iNKT cell repertoire is modified by the enrichment of CD4+ iNKT cells, a subset able to generate Th2 cytokines that can inhibit the expansion of tumor Ag-specific CD8+ T cells. Because CD4+ iNKT cells appear inefficient in tumor defense and may even favor tumor growth and recurrence, novel iNKT-targeted therapies should restore CD4- iNKT cells at the tumor site and specifically induce Th1 cytokine production from all iNKT cell subsets.",
author = "Gabriel Bricard and Valerie Cesson and Estelle Devevre and Hanifa Bouzourene and Catherine Barbey and Nathalie Rufer and Im, {Jin S.} and Alves, {Pedro M.} and Olivier Martinet and Nermin Halkic and Cerottini, {Jean Charles} and Pedro Romero and Porcelli, {Steven A.} and MacDonald, {H. Robson} and Speiser, {Daniel E.}",
year = "2009",
month = "4",
day = "15",
doi = "10.4049/jimmunol.0711086",
language = "English (US)",
volume = "182",
pages = "5140--5151",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors

AU - Bricard, Gabriel

AU - Cesson, Valerie

AU - Devevre, Estelle

AU - Bouzourene, Hanifa

AU - Barbey, Catherine

AU - Rufer, Nathalie

AU - Im, Jin S.

AU - Alves, Pedro M.

AU - Martinet, Olivier

AU - Halkic, Nermin

AU - Cerottini, Jean Charles

AU - Romero, Pedro

AU - Porcelli, Steven A.

AU - MacDonald, H. Robson

AU - Speiser, Daniel E.

PY - 2009/4/15

Y1 - 2009/4/15

N2 - Invariant NKT cells (iNKT cells) recognize glycolipid Ags via an invariant TCR α-chain and play a central role in various immune responses. Although human CD4+ and CD4- iNKT cell subsets both produce Th1 cytokines, the CD4+ subset displays an enhanced ability to secrete Th2 cytokines and shows regulatory activity. We performed an ex vivo analysis of blood, liver, and tumor iNKT cells from patients with hepatocellular carcinoma and metastases from uveal melanoma or colon carcinoma. Frequencies of Vα24/Vβ11 iNKT cells were increased in tumors, especially in patients with hepatocellular carcinoma. The proportions of CD4+, double negative, and CD8α+ iNKT cell subsets in the blood of patients were similar to those of healthy donors. However, we consistently found that the proportion of CD4+ iNKT cells increased gradually from blood to liver to tumor. Furthermore, CD4+ iNKT cell clones generated from healthy donors were functionally distinct from their CD4- counterparts, exhibiting higher Th2 cytokine production and lower cytolytic activity. Thus, in the tumor microenvironment the iNKT cell repertoire is modified by the enrichment of CD4+ iNKT cells, a subset able to generate Th2 cytokines that can inhibit the expansion of tumor Ag-specific CD8+ T cells. Because CD4+ iNKT cells appear inefficient in tumor defense and may even favor tumor growth and recurrence, novel iNKT-targeted therapies should restore CD4- iNKT cells at the tumor site and specifically induce Th1 cytokine production from all iNKT cell subsets.

AB - Invariant NKT cells (iNKT cells) recognize glycolipid Ags via an invariant TCR α-chain and play a central role in various immune responses. Although human CD4+ and CD4- iNKT cell subsets both produce Th1 cytokines, the CD4+ subset displays an enhanced ability to secrete Th2 cytokines and shows regulatory activity. We performed an ex vivo analysis of blood, liver, and tumor iNKT cells from patients with hepatocellular carcinoma and metastases from uveal melanoma or colon carcinoma. Frequencies of Vα24/Vβ11 iNKT cells were increased in tumors, especially in patients with hepatocellular carcinoma. The proportions of CD4+, double negative, and CD8α+ iNKT cell subsets in the blood of patients were similar to those of healthy donors. However, we consistently found that the proportion of CD4+ iNKT cells increased gradually from blood to liver to tumor. Furthermore, CD4+ iNKT cell clones generated from healthy donors were functionally distinct from their CD4- counterparts, exhibiting higher Th2 cytokine production and lower cytolytic activity. Thus, in the tumor microenvironment the iNKT cell repertoire is modified by the enrichment of CD4+ iNKT cells, a subset able to generate Th2 cytokines that can inhibit the expansion of tumor Ag-specific CD8+ T cells. Because CD4+ iNKT cells appear inefficient in tumor defense and may even favor tumor growth and recurrence, novel iNKT-targeted therapies should restore CD4- iNKT cells at the tumor site and specifically induce Th1 cytokine production from all iNKT cell subsets.

UR - http://www.scopus.com/inward/record.url?scp=65249176389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249176389&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0711086

DO - 10.4049/jimmunol.0711086

M3 - Article

C2 - 19342695

AN - SCOPUS:65249176389

VL - 182

SP - 5140

EP - 5151

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -